New Virtual Screening Strategy Identifies Existing Drug that Inhibits COVID-19 Virus

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational Biology.

With the COVID-19 pandemic causing illness and death worldwide, better treatments are urgently needed. One shortcut could be to repurpose existing drugs that were originally developed to treat other conditions. Computational methods can help identify such drugs by simulating how different drugs would interact with SARS-CoV-2, the virus that causes COVID-19.

To aid virtual screening of existing drugs, Zhang and colleagues combined multiple computational techniques that simulate drug-virus interactions from different, complimentary perspectives. They used this hybrid approach to screen 1,906 existing drugs for their potential ability to inhibit replication of SARS-CoV-2 by targeting a viral protein called RNA-dependent RNA polymerase (RdRP).

The novel screening approach identified four promising drugs, which were then tested against SARS-CoV-2 in lab experiments. Two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus. Further lab experiments showed that pralatrexate more strongly inhibited viral replication than did remdesivir, a drug that is currently used to treat some COVID-19 patients.

These findings suggest that pralatrexate could potentially be repurposed to treat COVID-19. However, this chemotherapy drug can prompt significant side effects and is used for people with terminal lymphoma, so immediate use for COVID-19 patients is not guaranteed. Still, the findings support the use of the new screening strategy to identify drugs that could be repurposed.

"We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics," Zhang says. He and his colleagues are now developing additional computational methods for generating novel molecular structures that could be developed into new drugs to treat COVID-19.

Zhang H, Yang Y, Li J, Wang M, Saravanan KM, Wei J, et al.
A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.
PLoS Comput Biol 16(12), 2020. doi: 10.1371/journal.pcbi.1008489

Most Popular Now

Alcidion Acquires UK Patient Flow Softwa…

Smart health technology provider Alcidion Group has today announced the strategic acquisition of ExtraMed, a UK company which specialises in providing NHS trusts with software that helps frontline staff make...

New AI Tool Tracks Evolution of COVID-19…

A new machine-learning program accurately identifies COVID-19-related conspiracy theories on social media and models how they evolved over time - a tool that could someday help public health officials combat...

Siemens Healthineers Completes Acquisiti…

Siemens Healthineers AG (Frankfurt: SHL) announced that it has successfully completed the acquisition of Varian Medical Systems, Inc. ("Varian"). The acquisition was previously announced on August 2, 2020. "With Varian, Siemens...

Artificial Intelligence Model Predicts w…

The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them. The immune defense is...

Commission Opens First European Innovati…

Following the launch of the European Innovation Council (EIC) and the announcement of the first funding opportunities, today the Commission opened the first EIC Accelerator calls. The funding worth over...

Talking Health Tech

Opinion Article by Andy Kinnear, Partnerships Director, Ethical Healthcare Consulting. Ethical is different. The guy who founded it, [chief executive] Thomas Webb, comes from an NHS background and he is very...

International Master in Digital Health i…

The Master of Digital Health, MDH (formerly - Master of Medical Informatics, MMI) at European Campus Rottal-Inn (ECRI) - a branch of the Deggendorf University of Applied Sciences (DIT) in Bavaria...

Call for Papers: DigiHealthDay-2021

12 November 2021 The DigiHealthDay 2021 is an International Symposium with the theme "Global Digital Health - Today, Tomorrow, and Beyond". The abstracts pertaining to the field of digital health and...

Proposal for a Regulation Laying Down Ha…

Artificial Intelligence (AI) is a fast evolving family of technologies that can bring a wide array of economic and societal benefits across the entire spectrum of industries and social activities...

Leeds Hospitals go Live with Agfa Health…

Leeds Teaching Hospitals NHS Trust (LTHT) has successfully implemented Agfa HealthCare's Enterprise Imaging (EI) solution, a unified platform complete with clinical tools, reporting and a workflow engine that will help...

Digital Mental Health Interventions for …

An increasing number of digital mental health interventions are designed for adolescents and young people with a range of mental health issues, but the evidence on their effectiveness is mixed...

CoolClinical.com has Developed the First…

Cool Clinical announced the release of the publication on the first Artificial Intelligence system for predicting outcomes of cancer treatment, using data from clinical trials. This is a breakthrough for...